A randomized controlled pilot study to evaluate the effect of an enteral formulation designed to improve gastrointestinal tolerance in the critically ill patient-the SPIRIT trial. by Jakob, Stephan M et al.
RESEARCH Open Access
A randomized controlled pilot study to
evaluate the effect of an enteral
formulation designed to improve
gastrointestinal tolerance in the critically ill
patient—the SPIRIT trial
Stephan M. Jakob1*, Lukas Bütikofer2, David Berger1, Michael Coslovsky2 and Jukka Takala1
Abstract
Background: Diarrhea is frequent in patients in intensive care units (ICU) and is associated with discomfort and
complications and may increase the length of stay and nursing workload.
Methods: This was a prospective, double-blind, randomized, controlled single-center pilot study to assess the
incidence and frequency of diarrhea and the respective effects of a modified enteral diet (intervention: Peptamen®
AF, rich in proteins, medium chain triglycerides and fish oil) compared to a standard diet (control: Isosource®
Energy) in 90 randomized adult patients (intervention, n = 46; control, n = 44) with an ICU stay ≥5 days and tube
feeding ≥3 days. Tube feeding was initiated within 72 h of ICU admission and continued up to 10 days. The caloric
goal was adjusted to needs by indirect calorimetry. Gastrointestinal function, nutritional intake, and nursing
workload were recorded. Follow-up was until 28 days after randomization.
Results: Median age was 63.3 (interquartile range (IQR) 51.0–73.2) years and Simplified Acute Physiology Score
(SAPS) II was 61.0 (IQR 47.8–74). Time to reach caloric goal (intervention: 2.2 (0.8–3.7) days (median, IQR); control: 2.0
(1.3–2.7) days; p = 0.16), length of time on study nutrition (intervention: 5.0 (3.6–6.4) days; control: 7.0 (5.3–8.7) days;
p = 0.26), and calorie intake (intervention: 18.0 (12.5–20.9) kcal/kg/day; control 19.7 (17.3–23.1) kcal/kg/day; p = 0.08)
did not differ between groups, with a higher protein intake for Peptamen® group (1.13 (0.78–1.31) g/kg/day vs 0.80
(0.70–0.94); p < 0.001). No difference in diarrhea incidence (intervention group: 29 (64%); control group: 31 (70%);
p = 0.652), use of fecal collectors (23 (51%) vs. 24 (55%); p = 0.83), or diarrhea-free days (161 (64%) vs 196 (68%);
p = 0.65) was found. Nursing workload and cost for diarrhea care were not different between the groups. In a
post-hoc analysis, adjusted for treatment group, age, sex, and SAPS II score, diarrhea was associated with length of
mechanical ventilation (9.5 (6.0–13.1) vs. 3.9 (3.2–4.6) days; p = 0.006) and length of ICU stay (11.0 (8.9–13.1)
vs. 5.0 (3.8–6.2) days; p = 0.001).
Conclusions: In this pilot study, we found a high incidence of diarrhea, which was not attenuated by Peptamen®
AF. Patients with diarrhea stayed longer in the ICU.
Trial registration: ClinicalTrials.gov identifier, NCT01581957. Registered on 18 April 2012.
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Background
Gastrointestinal dysfunction is common in critically ill
patients with prolonged intensive care unit (ICU) stay
[1], and diarrhea is one of the leading clinical symptoms
[2–5]. The causes of diarrhea are multifactorial and in-
clude recent abdominal surgery, infection, decreased
gastrointestinal perfusion, and antibiotics. In a prospect-
ive study in patients during the first 2 weeks of ICU stay,
the combination of enteral nutrition covering >60% of
the energy target and antibiotics or antifungal drugs
increased the incidence of diarrhea [6].
The inability to absorb sufficient amounts of nutrition
can increase muscle wasting and prolong recovery from
critical illness [7]. Attempts to reduce diarrhea using
fiber-enriched enteral formulas have been disappointing
in ICU patients [8–11]. Diarrhea, independent of its rea-
son, may predispose patients to a risk of malnutrition
and development of decubitus ulcers. It causes substan-
tial discomfort for patients and is likely to add to the
workload of nurses and the cost of care.
There is a wide range of diarrhea incidence reported
in recent randomized clinical studies (14% [6], 19–23%
[12], 22–26% [13], 26–29% [14], and 33–92% [15]),
partly related to patient population and varying diarrhea
definition. Reports on diarrhea-related costs are scarce.
We performed a pilot study to test the effect of a new
enteral formula on the frequency of diarrhea and gastro-
intestinal tolerance, and on all diarrhea-related costs in
ICU long-stayers. The purpose of the study was also to
gain information for the design of a future confirmatory
trial. The tested formula has a high energy density in
order to reduce the necessary feeding volume, enzymati-
cally hydrolyzed whey protein to improve absorption
[16], and its lipid fraction contains 50% medium chain
triglycerides and fish oil due to their possible benefits in
inflammatory states [17].
Methods
This study was approved by the local Ethics Committee
(KEK Bern, 060/12) and is registered at clinicalTrials.gov
(NCT01581957). Informed consent was obtained from
each patient or from a close relative. The study was
designed as a prospective, double-blind, randomized,
controlled single-center pilot study, where Peptamen®
AF was compared in a 1:1 allocation to a standard
formula (Isosource® Energy) with the same amount of
caloric density. The allocation sequence was generated
by an independent statistician not involved in the final
analysis of the trial. It was based on computer generated
random numbers in randomly varying blocks of four
and six using the statistical software package Stata
(StataCorp LP, College Station, TX, USA). Randomization
was stratified by the presence or absence of diarrhea at the
time of randomization. The study was conducted from 8
January 2013 (first patient included) until 29 August 2014
(last follow-up).
Objectives
The primary objective was to evaluate diarrhea and other
gastrointestinal symptoms in critically ill patients with
prolonged ICU stay who are either fed with Peptamen® AF
or Isosource® Energy. Secondary objectives were determin-
ation of inflammatory status, organ function, workload
and cost, and safety of patients fed with either one of the
two products. Accordingly, the primary outcomes were
diarrhea-free days and number of diarrhea events per day
during enteral nutrition administration in the ICU. Diar-
rhea was assessed according to the definition by Whelan
et al. [18] from start of enteral nutrition until the end of
enteral feeding or ICU discharge, whichever came first.
Whelan assigned scores to three categories of stool
amounts (<100 g, 100–200 g, >200 g) and four categories
of stool consistencies (hard and formed, soft and formed,
loose and unformed, liquid), ranging from 1 (<100 g, hard
and formed) to 12 (>200 g, liquid). Diarrhea is defined as
a score of 15 or more during 1 day. A list of the secondary
outcomes is provided in Additional file 1.
Inclusion and exclusion criteria
Inclusion criteria were medical and surgical ICU patients
≥18 years with an expected ICU stay of ≥5 days and antici-
pated tube feeding for ≥3 days. Exclusion criteria were the
presence of contraindications for enteral nutrition or
placement of an enteral feeding tube, patients receiving
enteral nutrition with ≥75% of caloric goal already admin-
istered, restrictions in full intestinal support, parenteral
nutrition of any kind unless due to enteral nutrition in-
tolerance, a history of allergy or intolerance to study prod-
uct components (test or control product), nonfunctional
gastrointestinal tract, limited care, and participation in
another interventional trial during the last month.
Test products
The active product, Peptamen® AF, is a liquid tube-
feeding calorie-dense formula (1.5 Kcal/ml) not contain-
ing fibers. It has a high whey protein concentration de-
livering 25% of the energy by proteins, 39% by lipids,
and 36% by carbohydrates.
The control product, Isosource® Energy, is a liquid
tube-feeding, calorie-dense formula (1.5 Kcal/ml) with-
out fibers, delivering 16% of the energy by protein, 35%
by lipids, and 50% by carbohydrates. The exact compos-
ition of both formulas is indicated in Additional file 1
(Table S6).
Feeding protocol
Patients in the trial received tube feeding initiated 0 to
72 h post-ICU admission. They received either Peptamen®
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AF or Isosource® Energy. The caloric target was 25 Kcal/
kg/day body weight (taken from medical records or rela-
tives, or estimated by medical staff ) to be reached on the
third day after enteral nutrition was started. The quantity
was subsequently adjusted to caloric estimates by indirect
calorimetry to be performed whenever possible during the
first night after study start, 3 days afterwards, at end of
nutrition with the study product, and 2 days afterwards if
still intubated. The total formula intake was monitored via
the Patient Data Management System (PDMS) as described
below. Tube feeding could be interrupted for clinical
reasons (cardiovascular instability, invasive interventions,
reanimation, severe diarrhea, high gastric residual volumes
or vomiting, and transportation). The study period on the
Fig. 1 Study CONSORT diagram. GI gastrointestinal
Table 1 Patient characteristics
Peptamen® AF (n = 46) Isosource® Energy (n = 44)
Age, years n = 46 65.3 (52.6–75.3) n = 44 61.6 (48.6–71.3)
Sex, male n = 46 33 (72%) n = 44 28 (64%)
Body mass index, kg/m2 n = 41 28.8 (25.1–34.2) n = 41 27.8 (23.5–31.5)
APACHE II admission diagnosis n = 44 28.5 (22.3–32.8) n = 42 27.5 (22.0–33.3)
SAPS II admission diagnosis n = 46 60.5 (46.5–74.0) n = 44 61.5 (48.5–75.5)
SOFA n = 45 8.0 (6.0–11.0) n = 44 7.0 (5.0–10.0)
Mechanical ventilation n = 46 43 (94%) n = 44 43 (98%)
Treated with vasoactive drugs n = 46 31 (67%) n = 44 29 (66%)
Diabetes n = 46 13 (28%) n = 44 8 (18%)
Residual gastric volume at study inclusion, ml n = 42 35.0 (10.0–112.5) n = 43 50.0 (20.0–100.0)
Presence of diarrhea at study inclusion n = 46 5 (11%) n = 44 4 (9%)
Blood glucose at study inclusion, mmol/l n = 46 7.8 (6.8–8.9) n = 44 8.3 (6.9–9.4)
Continuous variables are presented as median (interquartile range) and categorical variables as number of patients (%)
APACHE Acute Physiology and Chronic Health Evaluation, SAPS Simplified Acute Physiology Score, SOFA Sequential Organ Failure Assessment
Jakob et al. Critical Care  (2017) 21:140 Page 3 of 10
product lasted a maximum of 10 days. Afterwards, patients
were switched to standard enteral nutrition if still required.
According to internal nursing guidelines, a fecal collector
was administered when diarrhea was present or more than
three stool passages occurred per shift, but always at the
discretion of the treating physician who also evaluated the
presence of contraindications (leuco- or severe throm-
bopenia, rectal obstruction). Standard physiological
parameters were continuously recorded in a PDMS
(Centricity Critical Care Clinisoft®; General Electrics,
Helsinki, Finland). Study-related additional parameters
(diarrhea, material costs based on Additional file 1 (Table
S5), and nursing workload) were recorded in the same
PDMS using specifically designed case report forms which
were later exported to a database provided by the local
clinical trial unit (CTU). Due to logistic reasons at the
bedside, the nurses did not always record consistency and
the number of stools exactly at the same time. In such
cases, the closest entries for consistency and stool number
were merged off-line. In patients with fecal collectors
where the content of the collector was measured only
once per day, the frequency and number of individual
stool events could not be assessed. Patient-days with fecal
collectors were therefore omitted for the characterization
of the stool events and the calculation of the Whelan
score (Additional file 1: Table S1).
Patients were followed-up daily until 2 days after the
study end. An additional follow-up visit was conducted
28 days after randomization. There was independent on-
site monitoring provided by the CTU to ensure Good
Clinical Practice (GCP) compliance and data quality.
Adverse and serious adverse events were recorded
according to GCP Guidelines and are reported in
Additional file 1 (Table S7–S9).
Statistics
Prior to the current pilot study, we did not formally
assess and quantify diarrhea in our patients. Due to the
pilot character of the study, a sample size calculation
was therefore not performed. The active group and the
control group both had a target sample size of n = 45.
All randomized patients were included in the primary
Fig. 2 Number of stool events per day in each treatment group. CI confidence interval
Table 2 Nutritional intake
Peptamen® AF (n = 46) Isosource® Energy (n = 44) Treatment effect p value
n Median (IQR) n Median (IQR) Median differencea (95% CI)
Calorie intake, Kcal/kg/day 41 18.0 (12.5–20.9) 38 19.7 (17.3–23.1) −2.6 (−5.3 to 0.2) 0.08
Protein intake, g/kg/day 41 1.13 (0.78–1.31) 38 0.80 (0.70–0.94) 0.27 (0.12–0.43) <0.001
Accumulated caloric deficit during EN/day, Kcal 45 −410 (−984 to −115) 43 −171 (−455 to −4) −222 (−438 to −45) 0.014
n Median (95% CI) n Median (95% CI) HR (95% CI)
Length of EN, days 46 5.0 (3.6– to 6.4) 44 7.0 (5.3– to 8.7) 1.35 (0.80–2.26) 0.26
Time to reach the full caloric goal, days 46 2.2 (0.8– to 3.7) 44 2.0 (1.3– to 2.7) 0.70 (0.42–1.16) 0.16
n No. of events (pd) n No. of events (pd) Rate ratio (95% CI)
Days with parenteral nutrition supplementation 46 5 (253 pd) 44 2 (287 pd) 2.84 (0.28–28.61) 0.38
a Hodges–Lehmann median differences
CI confidence interval, EN enteral nutrition, HR hazard ratio, IQR interquartile range, pd person days
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analysis in the arm to which they were randomized re-
gardless of any protocol violations (intention-to-treat
principle). If a fecal collector was administered, the
number of stool events could not be counted. As a crude
estimate of stool events in these patients, the amount of
stool in the fecal collector was divided by the average
amount of stool per event from all patient days without
the fecal collector in the respective group.
Patient characteristics are presented as median and
interquartile range (IQR) and number and percentage of
patients for continuous and categorical data, respectively.
The two primary outcomes were analyzed by negative
binomial (number of diarrhea events) and mixed effects
logistic regression (diarrhea-free days) with the treatment
group as covariate. For a sensitivity analysis, the regression
models were adjusted for baseline diarrhea or for antibi-
otics prescription, respectively. Secondary endpoints were
analyzed by Wilcoxon rank-sum tests (non-normal con-
tinuous outcomes), Student t tests (normal continuous
outcomes), Fisher’s exact test (binary outcomes), Poisson
regressions with robust standard errors (count outcomes),
and Cox proportional hazard models (time-to-event
outcomes). The treatment effect is presented as inci-
dence rate ratio (count outcomes), risk ratio (binary
outcomes), mean difference (normal continuous outcomes),
Hodges–Lehmann median differences (non-normal con-
tinuous outcomes), or hazard ratio (HR; time-to-event out-
comes) with 95% confidence interval (CI). Line listings and
descriptive statistics were used to analyze adverse event
data. In a post-hoc analysis, patients that did or did not
experience diarrhea during the course of enteral nutrition
were compared. The analysis was adjusted for treatment
group, age, sex, and Simplified Acute Physiology Score
(SAPS) II admission diagnosis using negative binomial
(number of diarrhea events), Poisson regression with robust
standard errors (count outcomes), median regression (con-
tinuous outcomes) or Cox regression (time-to-event out-
comes). Results are reported as incidence rate ratio, median
difference, and HR with 95% CI, respectively.
Results
Ninety patients were included in the study (intervention
group 46, controls 44; Fig. 1). Median age was 63.3 (IQR
51.0–73.2) years and SAPS II was 61.0 (IQR 47.8–74).
Table 3 Diarrhea-associated events
Peptamen® AF (n = 46) Isosource® Energy (n = 44) Treatment effect p value
n n (%) with event n n (%) with event Risk ratio (95% CI)
Patients that experienced diarrhea during their ICU stay 45 29 (64%) 44 31 (70%) 0.91 (0.68–1.22) 0.65
Patients receiving a fecal collector during their ICU stay 45 23 (51%) 44 24 (55%) 0.94 (0.63–1.39) 0.83
n No. of events (pd) n No. of events (pd) Rate ratio (95% CI)
Days with interruption of EN due to diarrhea 46 0 (253 pd) 44 2 (287 pd) nd 0.28
n Median (IQR) n Median (IQR) Median differencea (95% CI)
Total costs of diarrhea per patient/day, CHF 45 3.66 (0.00–8.73) 44 2.60 (0.00–6.39) 0.00
(−0.36 to 2.70)
0.35
Nurse workload per patient/day, min 45 17.0 (0.0–38.5) 44 13.1 (0.0–21.5) 2.5 (−0.7 to 11.8) 0.28
a Hodges–Lehman median differences
CI confidence interval, EN enteral nutrition, ICU intensive care unit, IQR interquartile range, nd not defined, pd person days
Table 4 Primary endpoints
Peptamen® AF (n = 46) Isosource® Energy (n = 44) Rate or risk ratio (95% CI) p value
Stool events
Intention to treat 542 (253 pd) 415 (287 pd) 1.34 (0.89 to 2.02) 0.16
Adjusted for baseline diarrhea 542 (253 pd) 415 (287 pd) 1.28 (0.86 to 1.90) 0.23
Adjusted for antibiotics prescription 542 (253 pd) 415 (287 pd) 1.34 (0.89 to 2.02) 0.16
Per protocola 527 (237 pd) 401 (273 pd) 1.41 (0.92 to 2.15) 0.11
Diarrhea-free days
Intention to treat 161 (64%) 196 (68%) 0.82 (0.36 to 1.90) 0.65
Adjusted for baseline diarrhea 161 (64%) 196 (68%) 0.83 (0.38 to 1.82) 0.64
Adjusted for antibiotics prescription 161 (64%) 196 (68%) 0.83 (0.36 to 1.92) 0.66
Per protocola 149 (63%) 185 (68%) 0.82 (0.34 to 1.96) 0.65
an = 37 in both groups
CI confidence interval, pd person days
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Five (11%; Peptamen® AF group) and four (9%; Iso-
source® Energy group) patients, respectively, had diar-
rhea at study inclusion. Gastric residual volumes did not
differ between groups at study inclusion (Table 1).
Seventy-three (81%) patients received antibiotics during
the course of the study, while 65 (72%) were on antibi-
otics at study inclusion.
The time taken to reach the caloric goal and the length
of time on study nutrition were not different between
groups (Peptamen® AF: 2.2 (0.8–3.7) days and 5.0 (3.6–6.4)
days; Isosource® Energy: 2.0 (1.3–2.7) days and 7.0 (5.3–8.7)
days; p = 0.16 and p = 0.26, respectively; Table 2). Sixty
patients experienced diarrhea during their ICU stay (Pepta-
men® AF group: 29 (64%); Isosource® Energy group: 31
(70%); p = 0.652). Twenty three (51%) of the Peptamen®
group and 24 (55%) patients of the Isosource® group re-
ceived a fecal collector during the study period because of
diarrhea (p = 0.83; Table 3). The numbers of diarrhea-free
days were 161 (64%) and 196 (68%) for Peptamen® AF and
Isosource® Energy, respectively (p = 0.65). Stool events per
patient ICU days were comparable between groups (Table 4
and Fig. 2 and Additional file 1: Table S1 and S2). In each
group, 15 patients received prokinetic drugs (metoclopra-
mide and/or erythromycin). The numbers did also not dif-
fer in the per protocol analysis and if only patients without
fecal collectors were analyzed. Likewise, the results did not
differ between groups when adjusted for baseline diarrhea
or for antibiotics prescription (Fig. 2). The material costs
were 3.09 (IQR 0.00–7.58) CHF/day/patient. Respective
costs per day for patients with diarrhea were CHF 6.31
(0.00–17.11). The median nursing workload in all patients
was 15.0 (0.0–27.0) min/day/patient, and for days with
diarrhea 40.0 (17.5–74.4) min/patient and for days with
fecal collector 20.0 (6.4–52.5) min/patient. Nursing work-
load and cost for diarrhea care were similar in both groups
(Table 3 and Additional file 1: Table S3). Therapeutic
intervention scoring system (TISS-76) per day were 46.0
(40.1–54.0) and 46.3 (42.2–50.3) (p = 0.83).
Some small numerical differences in secondary end-
points between the two groups were identified, but with-
out an overall trend specific to one product, and without
clinical relevance (Tables 2, 3, 5, and 6). Both groups
received a similar percentage of prescribed calories
(median 85% (IQR 71%–95%) for Peptamen®, 90% (84%–
96%) for Isosource®®; p = 0.07) and reached the caloric
goal in equal time (2.2 (0.8–3.7) days for Peptamen®, 2.0
(1.3–2.7) days for Isosource®®; p = 0.16; Fig. 3). Median
caloric intake did not differ between groups (Peptamen®
AF: 18.0 (12.5–20.9) kcal/kg/day; Isosource® Energy: 19.7
(17.3–23.1) kcal/kg/day; p = 0.08), with a higher protein
intake for the Peptamen® group (1.13 (0.78–1.31) g/kg/
day vs 0.80 (0.70–0.94) g/kg/day; p < 0.001). Differences
were found for the accumulated caloric deficit during
enteral nutrition/day, which yielded −410 (−984 to
−115) kcal for Peptamen® AF and −171 (−455 to −4) kcal
for Isosource® Energy (p = 0.014; Table 2).
In the Isosource® group, three patients had positive
stool samples for Clostridium difficile. There was no
noticeable difference regarding adverse events or ser-
ious adverse events between the two treatment groups
(Additional file 1: Table S7–S9). No ‘certain’ or ‘probable’
product-related events were identified. The length of
mechanical ventilation and ICU and hospital stay were
similar in both groups (Table 6).
Table 5 Albumin and glucose
Peptamen® AF (n = 46) Isosource® Energy (n = 44) Treatment effect p value
n Median (IQR) n Median (IQR) Median differencea (95% CI)
Serum albumin at baseline 39 21.0 (17.0–25.0) 42 21.3 (18.0–24.0) 0.0 (−2.0 to 2.0) 0.93
Serum albumin at treatment end or at ICU discharge 17 21.0 (19.0–26.0) 19 23.0 (18.0–26.0) 0.00 (−3.00 to 3.00) 0.99
n No. of events (pd) n No. of events (pd) Rate ratio (95% CI)
Number of events outside the 4.5–10
mmol/l glycemic range
46 425 (253 pd) 44 582 (287 pd) 0.83 (0.54–1.28) 0.39
aHodges–Lehmann median differences
CI confidence interval, ICU intensive care unit, IQR interquartile range, pd person days
Table 6 Length of stay, mechanical ventilation and secondary infections
Peptamen® AF (n = 46) Isosource® Energy (n = 44) Treatment effect p value
n No. of events (pd) n No. of events (pd) Rate ratio (95% CI)
Secondary infections 46 19 (253 pd) 44 19 (287 pd) 1.13 (0.70 to 1.84) 0.61
n Median time (95% CI) n Median time (95% CI) HR (95% CI)
Length of mechanical ventilation, days 46 6.2 (4.8–7.7) 44 7.0 (4.7–9.3) 1.33 (0.83–2.11) 0.23
Length of ICU stay, days 46 7.0 (5.3–8.7) 44 10.0 (6.6–13.4) 1.27 (0.81–2.02) 0.30
Length of hospital stay, days 46 31.0 (27.0–35.0) 44 36.0 (29.9–42.1) 1.01 (0.54–1.89) 0.97
CI confidence interval, HR hazard ratio, ICU intensive care unit, pd person days
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At baseline, patients with diarrhea suffered from higher
scores of disease severity (Acute Physiology and Chronic
Health Evaluation (APACHE) II and SAPS II; Table 7). A
post-hoc analysis adjusted for treatment group, age, sex,
and SAPS II score showed that patients with diarrhea
remained longer on mechanical ventilation (9.5 (6.0–13.1)
days vs. 3.9 (3.2–4.6) days; p =0.006) and had longer stays
in the ICU (11.0 (8.9–13.1) days vs. 5.0 (3.8–6.2)
days; p =0.001) (Table 8).
Discussion
Diarrhea was present during one-third of all ICU days,
and roughly two-thirds of our target patient population
with a median ICU stay of 8 days experienced diarrhea.
The gastrointestinal symptoms were not influenced by the
nutritional product. Adjustment for baseline diarrhea
(roughly 10% of the patients) and use of antibiotics (61%)
did not alter the results. Associated abdominal discomfort
was absent or mild-to-moderate in patients in whom it
could be assessed, but the nursing workload related to
diarrhea was high. The accumulated caloric deficit was
<500 Kcal/day during the study period (428 Kcal/day for
patients with diarrhea over both groups) but may have
been underestimated if malabsorption occurred during
periods of diarrhea. The higher caloric deficit in the Pepta-
men® AF group may be attributed to a higher rate of tube
feeding interruptions per nutrition day. Most of the ad-
verse events were judged as unrelated to the study product
and the latter was withdrawn in only 3–5% of events.
Previous studies have reported diarrhea incidences ran-
ging from around 15% to over 50% [19–21]. Some of the
differences can be explained by a differing case mix and def-
inition of diarrhea. The patients in the present study had
several risk factors for diarrhea which were likely to con-
tribute to the observed high diarrhea incidence: use of a
hyperosmolar formula in both study groups [22]; a relatively
high administration rate of the enteral nutrition [23]; the
presence of hypoalbuminemia in all study patients [24, 25];
and frequent use of antibiotics in 77% of patients [26, 27].
The composition of enteral feeding had no effect on
diarrhea or feeding tolerance. The higher protein con-
tent of the new formula was aimed to facilitate higher
protein intake, as recommended by recent guidelines
[28]. The relevance of protein intake in ICU patients re-
mains controversial [29]. Fewer surgical ICU patients
with deficits in protein intake during enteral nutrition
were discharged home [30]. In patients with pneumonia
and/or sepsis, higher protein administration decreased
mortality [31]. In contrast, a recent trial in patients with
acute lung injury was stopped prematurely because ad-
ministration of higher percentages of estimated protein
(76% vs. 54%) and energy needs (85% vs. 55%) increased
hospital mortality despite unchanged length of mechan-
ical ventilation or infection rates [32]. An enteral diet
rich in medium-chain triglycerides, carnitine, and tau-
rine increased protein and energy intake and reduced
Fig. 3 Kaplan-Meier plot for the time to reach the full caloric goal.
Patients not reaching the caloric goal are censored (at the end of
enteral nutrition)
Table 7 Baseline characteristics from post-hoc analysis
Patients with diarrhea (n = 60) Patients without diarrhea (n = 30) p value
Receiving Peptamen® AF n = 60 29 (48%) n = 30 17 (57%) 0.51
Age, years n = 60 63.7 (51.0–74.3) n = 30 61.7 (50.5–72.8) 0.71
Sex, male n = 60 41 (68%) n = 30 20 (67%) 1.00
Body mass index, kg/m2 n = 54 28.1 (23.6–33.8) n = 28 28.2 (23.9–32.6) 0.83
APACHE II score n = 57 30.0 (25.0–36.0) n = 29 26.0 (20.0–30.0) 0.005
SAPS II score n = 60 66.0 (53.5–76.8) n = 30 52.0 (43.8–63.8) 0.003
Diabetes n = 60 12 (20%) n = 30 9 (30%) 0.30
Residual gastric volume at study inclusion, ml n = 58 41.0 (20.0–112.5) n = 27 30.0 (10.0–80.0) 0.19
Presence of diarrhea at study inclusion n = 60 8 (13%) n = 30 1 (3%) 0.26
Blood glucose at study inclusion, mmol/l n = 60 8.2 (7.0–9.4) n = 30 8.0 (6.6–8.9) 0.43
Continuous variables are presented as median (interquartile range) and categorical variables as number of patients (%)
APACHE Acute Physiology and Health Evaluation, SAPS Simplified Acute Physiology Score
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feeding intolerance and diarrhea in a single-blind study
in ICU patients with overall lower diarrhea incidence
than in our study [33]. In our study, the differences in
protein intake between the study groups were substan-
tial, but were not associated with differences in diarrhea
incidence or any of the secondary clinical outcomes.
There are limited data on resource use for patients
with diarrhea, and the few published studies focus on
Clostridium difficile-associated diarrhea. For example, a
multicenter retrospective study reporting adjusted out-
comes found longer ICU (8.3 days vs. 6.6 days; p < 0.01)
and hospital stay (13.2 days vs. 8.5 days; p < 0.01) and
almost 40% increased total cost for patients with com-
pared to those without C. difficile-associated diarrhea
[34]. Nursing workload for diarrhea care has not been
addressed so far. In our study, with a low incidence of C.
difficile, the average nursing workload for diarrhea care
was more than 3 h/patient, with a moderate increase in
Table 8 Post-hoc comparison of patients with and without diarrhea
Patients with diarrhea (n = 60) Patients without diarrhea (n = 30) Effect of diarrhea p value
n n (%) with event n n (%) with event Risk ratio (95% CI)
Death 60 16 (27%) 29 7 (24%) 0.68 (0.26 to 1.78) 0.44
n Median (IQR) n Median (IQR) Median difference (95% CI)
Maximal abdominal pain per patient/staya 42 0.00 (0.00–3.00) 19 2.00 (0.00–4.00) −0.8 (−2.9 to 1.4) 0.47
Mean abdominal pain per patient/staya 42 0.00 (0.00–1.00) 19 0.67 (0.00–2.00) −0.4 (−1.4 to 0.7) 0.49
Accumulated caloric deficit 3 days after
start of EN, Kcal
59 −888 (−1828 to −266) 29 −924 (−1521 to −230) −175 (−813 to 463) 0.59
Accumulated caloric deficit during
EN/day, Kcal
59 −268 (−521 to −41) 29 −455 (−1008 to −78) 248 (−67 to 563) 0.12
Percentage of cumulative calories
delivered vs. prescribed during EN
59 0.90 (0.81–0.96) 29 0.85 (0.74–0.95) 0.01 (−0.10 to 0.11) 0.91
Serum albumin at baseline, g/L 53 20.0 (16.0–23.0) 28 24.0 (21.0–26.0) −2.6 (−5.2 to −0.0) 0.050
Serum albumin 3 days after EN start, g/L 43 18.0 (14.0–24.0) 11 23.0 (17.0–25.0) −0.7 (−4.7 to 3.2) 0.72
Serum albumin at treatment end or
at ICU discharge, g/L
23 20.0 (17.0–26.0) 13 24.0 (21.0–25.0) −0.8 (−4.7 to 3.2) 0.69
n No. of events (pd) n No. of events (pd) Rate ratio (95% CI)
Stool events 60 911 (418 pd) 30 46 (122 pd) 4.60 (2.98–7.11) <0.001
Days with interruption of EN due to diarrhea 60 2 (418 pd) 30 0 (122 pd) nd
Days with presence of electrolyte and
acid-base disturbances
60 350 (418 pd) 30 102 (122 pd) 0.97 (0.88–1.09) 0.64
Days with presence of electrolyte disturbances 60 346 (418 pd) 30 98 (122 pd) 1.01 (0.90–1.13) 0.88
Days with presence of acid-base disturbances 60 42 (418 pd) 30 17 (122 pd) 0.48 (0.27–0.84) 0.010
Changes in intra-abdominal pressure 60 250 (418 pd) 30 53 (122 pd) 1.21 (0.68–2.13) 0.51
Diarrhea due to medication 60 18 (418 pd) 30 0 (122 pd) nd
Days with drug interfering with the
passage of nutrition
60 150 (418 pd) 30 26 (122 pd) 1.50 (0.76–2.95) 0.25
Number of events outside the 4.5–10
mmol/l glycemic range
60 748 (418 pd) 30 259 (122 pd) 0.58 (0.34–1.01) 0.05
Number of events above the 4.5–10
mmol/l glycemic range
60 738 (418 pd) 30 259 (122 pd) 0.58 (0.33–1.00) 0.05
Number of events below the 4.5–10
mmol/l glycemic range
60 10 (418 pd) 30 0 (122 pd) nd
Secondary infections 60 28 (418 pd) 30 10 (122 pd) 0.66 (0.36–1.20) 0.17
Days with mechanical ventilation 60 242 (418 pd) 30 68 (122 pd) 0.98 (0.78–1.24) 0.86
n Median time (95% CI) n Median time (95% CI) HR (95% CI)
Length of EN, days 60 8.0 (5.9–10.1) 30 4.0 (2.9–5.1) 0.36 (0.20–0.64) <0.001
Length of ICU stay, days 60 11.0 (8.9–13.1) 30 5.0 (3.8–6.2) 0.40 (0.23–0.71) 0.001
Length of hospital stay, days 60 36.0 (29.6–42.4) 30 31.0 (17.6–44.4) 0.67 (0.33–1.39) 0.29
Length of mechanical ventilation, days 60 9.5 (6.0–13.1) 30 3.9 (3.2–4.6) 0.46 (0.27–0.81) 0.006
Time to reach the full caloric goal, days 60 1.9 (0.9–3.0) 30 2.5 (1.7–3.3) 1.11 (0.59–2.07) 0.75
Effects from an adjusted analysis (for treatment group, age, sex, and Simplified Acute Physiology Score (SAPS) II admission diagnosis) are shown
aPatient-assessed, only in non-comatose patients
CI confidence interval, EN enteral nutrition, HR hazard ratio, ICU intensive care unit, IQR interquartile range, nd not defined, pd person days
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material costs. However, also in our study, patients with
diarrhea spent more days on mechanical ventilation and
in the ICU compared to those without. This finding
emphasizes the need for more research on potentially
preventable factors associated with diarrhea.
A limitation of our study is the relatively small number
of patients and the frequent use of fecal collectors,
although this is clinically indicated and potentially able to
decrease nursing workload. This prevented a more
detailed analysis of stool frequency. Nevertheless, we can
give a reliable estimate of stool events. Not using the fecal
collector would have interfered with estimates of diarrhea
cost and nursing workload as they occur in our unit.
Conclusions
We found that patients with diarrhea stayed longer in
the ICU. This demonstrates that diarrhea is a significant
problem in the ICU. While the data of this pilot study
do not indicate that modification of the protein and fat
content can attenuate the incidence of diarrhea, it does
show that a product like Peptamen® AF can effectively
deliver a high daily protein amount without overfeeding
the ICU patients. More research should be conducted to
reduce diarrhea in critically ill ICU long-stayers.
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